As the global medical landscape shifts under the weight of the "GLP-1 revolution," plastic surgeons are finding themselves at the intersection of innovative pharmacological weight management and reconstructive surgery. With the increasing popularity of medications like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro, Zepbound), a growing cohort of patients are entering the operating room having recently utilized—or currently utilizing—these potent GLP-1 receptor agonists (GLP1ra).
A landmark study published in the April issue of Plastic and Reconstructive Surgery®, the official journal of the American Society of Plastic Surgeons (ASPS), offers the first in-depth look at how these drugs influence outcomes for patients undergoing abdominal panniculectomy—a body contouring procedure aimed at removing excess skin and tissue following massive weight loss. The findings suggest that while these drugs are not a "red flag" for surgery, they do create a complex, nuanced profile of healing that surgeons must proactively manage.
Main Facts: A New Variable in the Operating Room
Body contouring procedures, particularly panniculectomy, have long been the gold standard for patients who have successfully navigated the challenges of massive weight loss. However, these surgeries are technically demanding and carry a risk profile centered on wound healing.
The core takeaway from the study conducted by Dr. Zachary Andrew Koenig and his colleagues at the West Virginia University School of Medicine is that the preoperative use of GLP-1 medications introduces a "mixed bag" of physiological effects. While the medications did not significantly increase the likelihood of catastrophic complications—such as severe infections or the need for emergency rehospitalization—they were statistically linked to a notable increase in delayed wound healing.
Interestingly, the study also uncovered a paradoxical benefit: GLP-1 users experienced a significantly lower rate of seroma, a common and often frustrating complication where fluid collects under the surgical site. This suggests that the pharmacological impact of GLP-1s on the body’s metabolic and inflammatory processes is far more intricate than previously understood, affecting soft tissue recovery in ways that are both challenging and advantageous.
A Decade of Data: The Chronology of the Study
To understand the impact of these drugs, the research team performed a comprehensive 10-year retrospective analysis, spanning from 2013 to 2023. This decade-long window is critical because it captures the period immediately preceding and following the explosion of GLP-1 prescriptions in the United States.
- 2013–2018 (The Pre-Trend Era): During the early years of the study, the prevalence of GLP-1 use among the patient population was relatively low. These patients were typically managing type 2 diabetes rather than using the medications primarily for weight loss.
- 2019–2021 (The Inflection Point): As GLP-1 receptor agonists began gaining widespread media attention and broader clinical approval for weight management, the researchers observed a sharp upward trend in usage among patients presenting for consultations at their institution.
- 2022–2023 (The Modern Landscape): By the final years of the study, 21.7% of all patients undergoing panniculectomy were active users of GLP-1 medications.
By filtering out patients who underwent concurrent bariatric or hernia surgeries, the researchers were able to isolate the specific impact of the medication on the panniculectomy site itself, providing a clean data set that reflects the "pure" experience of a body-contouring patient on these drugs.
Supporting Data: By the Numbers
The statistical analysis conducted by Dr. Koenig’s team reveals clear disparities between those on GLP-1 therapy and those who were not. While the body mass index (BMI) between the two groups remained consistent, the underlying health profiles differed significantly.
Patient Characteristics
Patients on GLP-1 therapy were more likely to present with comorbidities such as:
- Type 2 diabetes
- Chronic obstructive pulmonary disease (COPD)
- Hypertension
Surgical Outcomes: The Comparison
The data regarding post-surgical complications provides the most actionable insights for surgeons today:
- Delayed Wound Healing: This was the primary area of concern. Patients using GLP-1 medications exhibited an 18.5% rate of delayed healing, compared to just 7.5% in the non-GLP-1 group. This represents a more than two-fold increase in the risk of slow-closing wounds, which can lead to increased patient anxiety and additional clinical visits.
- Seroma Formation: In a surprising reversal, GLP-1 users were significantly less prone to seroma. Only 4.9% of the treatment group experienced this fluid buildup, compared to 14.0% in the control group.
- Equivalent Risks: Both groups showed no statistically significant differences in rates of surgical site dehiscence (reopening of the wound), infection, or the need for rehospitalization.
Official Responses and Clinical Perspectives
The medical community has received these findings as a necessary "first step" in formalizing guidelines. Dr. Zachary Andrew Koenig, the lead author, notes that the study highlights a "complex and nuanced interplay" between the medication and the body’s healing mechanisms.
"As GLP-1 receptor agonist medications become increasingly integrated into the care of patients undergoing body contouring, our findings suggest that these drugs may have subtle effects on wound healing, even if they don’t increase overall surgical risks," Dr. Koenig explained.
The research team emphasized that their data is particularly relevant given the location of their study. West Virginia, which currently holds one of the highest rates of GLP-1 prescriptions in the nation, provided a "front-row seat" to this trend. Their conclusions emphasize that while the drugs appear to be broadly safe from a perioperative standpoint, they are not entirely "neutral." Plastic surgeons are now being urged to move away from a "one-size-fits-all" approach and instead move toward a model of "proactive management" for patients on these therapies.
Implications: The Future of Body Contouring
The implications of this study are far-reaching, affecting both the surgeon’s office and the patient’s preoperative journey.
For the Plastic Surgeon
The primary implication is the need for enhanced vigilance. Surgeons may need to adjust their postoperative care protocols for patients on GLP-1s, perhaps by extending the duration of wound monitoring or utilizing specific advanced wound-care dressings to mitigate the risk of delayed healing. Furthermore, the reduction in seroma rates provides a valuable clinical talking point: while these drugs may delay the final healing date, they may simultaneously decrease the incidence of the most common post-panniculectomy nuisance.
For the Patient
Patients should be encouraged to have open, honest conversations with their surgical team regarding their GLP-1 usage. The "standard of care" is shifting toward a requirement that patients disclose these medications well in advance of surgery. This study suggests that patients should not necessarily be "cleared" for surgery without a discussion regarding the potential for longer recovery times or specific wound-healing strategies.
For the Medical Community
This study is a call to action for the development of standardized, formal guidelines. Currently, the landscape of GLP-1 use in elective surgery is being navigated on an individual, institution-by-institution basis. As the prevalence of these drugs continues to climb, the American Society of Plastic Surgeons and other governing bodies will likely need to synthesize this data into clinical practice recommendations.
Ultimately, the study serves as a reminder that the human body’s response to surgery is deeply affected by systemic metabolic factors. As we enter a new era of metabolic medicine, the surgical community must remain agile, utilizing the latest data to ensure that patients can achieve their aesthetic goals safely and effectively.
While the "GLP-1 era" presents new challenges for wound healing, it also offers a unique opportunity for surgeons to refine their techniques and protocols, ensuring that the transformative benefits of body contouring remain accessible and safe for the millions of patients seeking to complete their weight-loss journey.
About the Author
